

Number 768 • November 2018

# Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Propafenone 150 mg Tablet (DIN 02243324) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 29, 2018.** 

#### **PROPAFENONE HCL**

150 MG TABLET					
	00002243324	APO-PROPAFENONE	ΑΡΧ	\$ 0.2965	
	00002457172	MYLAN-PROPAFENONE	МҮР	\$ 0.2965	
	00000603708	RYTHMOL	BGP	\$ 1.2264	

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Propafenone 300 mg Tablet (DIN 02243325) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 29, 2018.** 

#### **PROPAFENONE HCL**

300 MG TABLET							
00002243325	APO-PROPAFENONE	АРХ	\$ 0.5227				
00002457164	MYLAN-PROPAFENONE	МҮР	\$ 0.5227				
00000603716	RYTHMOL	BGP	\$ 2.1617				

Alberta Blue Cross has been advised by Apotex Inc. and Pharmascience Inc. that the shortages for Apo-Methylphenidate 20 mg Tablet (DIN 02249332) and pms-Methylphenidate 20 mg Tablet (DIN 00585009) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 03, 2018.** 

#### **METHYLPHENIDATE HCL**

20 MG TABLET

00002249332	APO-METHYLPHENIDATE	ΑΡΧ	\$ 0.2326
00000585009	PMS-METHYLPHENIDATE	PMS	\$ 0.2326
0000005614	RITALIN	NOV	\$ 0.6615

## Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortage of the following products, Propafenone 150 mg Tablet (DIN 02343053) and Propafenone 300 mg Tablet (DIN 02343061) manufactured by Sanis Health Inc. and pms-Propafenone 300 mg Tablet (DIN 02294575) manufactured by Pharmascience Inc. were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description	Manufacturer
02243324	Apo-Propafenone 150 mg Tablet	Apotex Inc.
00603708	Rythmol 150 mg Tablet	BGP Pharma ULC
02243325	Apo-Propafenone 300 mg Tablet	Apotex Inc.
00603716	Rythmol 300 mg Tablet	BGP Pharma ULC

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Propafenone 150 mg Tablet (DIN 02243324) and Apo-Propafenone 300 mg Tablet (DIN 02243325) have been resolved.

As a result, the above products will no longer be considered temporary benefits for the ADBL after November 30, 2018.

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php** 



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.768 2018/11

